The Global HIV Vaccine Enterprise

The Global HIV Vaccine Enterprise
Uniting stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of—and future access to—an HIV vaccine

Learn more Strategic Plan

A renewed Strategic Plan

Uniting stakeholders to share knowledge, foster collaboration, enable solutions and to support the most critical issues, risks and challenges faced by the field

Increasing resources

Mobilizing new funding to support and grow the field of HIV vaccine research and development

Greater collaboration

Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts

DESIGN APPROACHES FOR CURRENT AND FUTURE HIV PREVENTION EFFICACY TRIALS

VIRTUAL WORKSHOP SERIES

October 2020 to May 2021

Presentations and panel discussions 1-3 available online

Late-breaking results from the Antibody Mediated Prevention (AMP) proof-of-concept trials evaluating whether infusions with VRC01, a broadly neutralizing antibody, can prevent HIV acquisition will be presented by Lawrence Corey of Fred Hutchinson Cancer Research Center during the HIV Research for Prevention HIV R4P // Virtual conference

Wednesday 27 January, 15:00 – 16:00 (UTC) Live channel 2

HIV & TB: An R&D tale of two vaccines

An HIV R4P // Virtual Satellite in partnership with the TuBerculosis Vaccine Initiative (TBVI).

SA03 Wednesday 27 January, 18:45 – 20:15 (UTC) channel 2

How HIV Vaccine R&D is enabling the rapid COVID-19 vaccine response

February 12, 2021/in News /by Roger Tatoud

In this presentation, Dr. Roger Tatoud, presents the finding of an investigation led by the Enterprise to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.

HIV R4P Virtual News

January 21, 2021/in Events /by Roger Tatoud

HIV vaccine highlights and spotlights – To help attendees manage their time and navigate a busy programme, the Enterprise has developed an HIV vaccine R&D roadmap which covers active immunization and passive immunization with broadly neutralizing antibodies (bNAbs), especially VRC01.

Timely topics

In 2012, the Enterprise launched Timely Topics in HIV Vaccines, a strategy series convening experts as rapidly as possible to analyze, address, and respond to unresolved and emerging priority issues in the field. Through an open call for proposals, the Enterprise is working to identify the most important strategic needs of the field and sponsoring think tanks, meetings, forums and other events to tackle these issues.

Submit a timely topic